Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks